Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 0.55 |
| ▸ | MPO | P05164 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 4/20 | 0.48 |
| ▸ | HTR1B | P28222 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970863 | 1.00 | HTR1A (1.00) | HTR1AHTR2AMPOHTR2CHTR2B | |
| SCHEMBL32669417 | 0.99 | HTR1A (0.98) | HTR1AHTR2AMPOHTR2CHTR2B | |
| SCHEMBL32669346 | 0.88 | HTR1A (0.78) | HTR1AHTR2AMPOHTR2CHTR2B | |
| SCHEMBL8548458 | 0.85 | HTR1A (0.74) | HTR1AHTR2AMPOHTR2CHTR2B | |
| SCHEMBL24723416 | 0.82 | HTR1A (0.70) | HTR1AHTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL32669272 | 0.81 | HTR2A (0.67) | HTR1AHTR2AMPOHTR2CHTR2B | |
| SCHEMBL32669438 | 0.80 | HTR1A (0.72) | HTR1AHTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL26508356 | 0.80 | HTR1A (0.66) | HTR1AHTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL32669276 | 0.79 | HTR1A (0.71) | HTR1AHTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL30916159 | 0.76 | HTR1A (1.00) | HTR1AHTR2AMPOHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4452986-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118055766-A | Magic and non-magic serotonin receptor agonist and its preparing process and usage | 库莱恩有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023225043-A1 | TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4251181-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251139-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | HTR1A 4/4885HTR2A 12/4885MPO 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.